Research shows that the effectiveness of Bavarian Nordic’s Mpox vaccine drops to undetectable levels after 6-12 months.

The World Health Organization (WHO) has announced the MVA-BN vaccine as the first vaccine against mpox to be added to its prequalification list. The prequalification approval is expected to facilitate ...

Two separate studies have shown that the efficacy of Bavarian Nordic’s vaccine against the deadly infectious disease wanes ...

The European Medicines Agency (EMA) has approved the use of Bavarian Nordic’s mpox vaccine in adolescents, increasing the ...

One dose of modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is moderately effective against mpox infection in at-risk communities.

With more than 200 mpox-related deaths reported globally, the EMA has approved Imvanex for adolescents aged 12-17 years.

The African health agency says that Rwanda has started a vaccination campaign against mpox with 1,000 doses it obtained from ...

This summary presents key updates in the health sector. Highlights include UnitedHealth's tech unit customers adopting ...

The vaccination campaign against mpox in the Democratic Republic of Congo is to begin on October 2, the public health ...

Saad B. Omer Mpox (formerly known as monkeypox) is back in the news. As of early September, the World Health Organization has ...

(RTTNews) - Bavarian Nordic A/S (BAVA) Thursday said that the European Commission has adopted the Committee for Medicinal Products for Human Use (CHMP) recommendation for the approval of a type II ...

Bavarian Nordic A/S, one of the only companies with a vaccine approved for mpox, has received regulatory approval in Europe ...